JPMorgan analyst Anupam Rama raised the firm’s price target on BridgeBio (BBIO) to $77 from $76 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio price target raised to $100 from $55 at Goldman Sachs
- BridgeBio Pharma’s Earnings Call Highlights Success and Challenges
- BridgeBio price target raised to $80 from $66 at Truist
- BridgeBio price target raised to $95 from $60 at TD Cowen
- BridgeBio price target raised to $81 from $73 at Oppenheimer